As part of our series focussing on research on medicines in Australia, we have added a product review of the use of febuxostat for chronic symptomatic hyperuricaemia in conditions where urate deposition has already occurred in adults with gout.
This publication focuses on the efficacy and safety of febuxostat and provides commentary from Dr Ken Cai, a Staff Specialist Rheumatologist at Westmead Hospital in Sydney and Clinical Senior Lecturer for the University of Sydney.
Please login below to download this issue (PDF)